- Home
- CTRM vs BCTX Comparison
CTRM vs BCTX Comparison
Compare CTRM & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTRM | BCTX |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | Cyprus | Canada |
| Employees | N/A | 4 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 24.1M |
| IPO Year | 2017 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CTRM | BCTX |
|---|---|---|
| Price | $2.13 | $2.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 74.8K | ★ 238.3K |
| Earning Date | 04-15-2026 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.66 | $0.61 |
| 52 Week High | $2.65 | $14.68 |
Technical Indicators
Market Signals| Indicator | CTRM | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.38 | 34.94 |
| Support Level | $1.95 | N/A |
| Resistance Level | $2.18 | $4.51 |
| Average True Range (ATR) | 0.15 | 0.22 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 47.04 | 22.94 |
Price Performance
Historical ComparisonAbout CTRM Castor Maritime Inc.
Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments namely (i) the dry bulk segment (ii) the containership segment and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.